CALR and B-cell chronic lymphocytic leukemia: Nevertheless, leukemic mice treated with an SpiD3 prodrug demonstrated elevated splenic CLL ecto-CALR expression and plasma immunostimulatory factors suggestive of an immunogenic response to treatment.